 |
|
Epidemiology and updated management for autoimmune liver disease
Nae-Yun Heo, Haeryoung Kim
Clin Mol Hepatol. 2023;29(1):194-196. Published online 2022 Dec 14 DOI: https://doi.org/10.3350/cmh.2022.0387
|
|
Citations to this article as recorded by
 Evaluation of autoimmune liver disease natural history in patients referred to Middle East Liver Diseases (MELD) center
Seyed Erfan Mehdi Nejad, Mohammad Heiat, Mohammad Javanbakht, Seyed Moayed Alavian, Mohammad Ali Abyazi Haris
BMC Gastroenterology.2024;[Epub] CrossRef Artemisia capillaris Thunb. Polysaccharide alleviates cholestatic liver injury through gut microbiota modulation and Nrf2 signaling pathway activation in mice
Jingyi Cai, Zhenyun Zhu, Yuanyuan Li, Qi Li, Tian Tian, Qian Meng, Tianming Wang, Yueming Ma, Jiasheng Wu
Journal of Ethnopharmacology.2024; 327: 118009. CrossRef JCAD, a new potential therapeutic target in cholestatic liver disease
Byoung Kuk Jang
Clinical and Molecular Hepatology.2024; 30(2): 166. CrossRef Comparison of four histological scoring systems for autoimmune hepatitis to improve diagnostic sensitivity
Soomin Ahn, Sook-Hyang Jeong, Eun Ju Cho, Kyoungbun Lee, Gilhyang Kim, Haeryoung Kim
Clinical and Molecular Hepatology.2023; 30(1): 37. CrossRef
|